The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | CLARITY-PanTumor01: sonesitatug vedotin in claudin 18.2+ gastric/GEJ cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, presents data from the Phase II CLARITY-PanTumor01 trial (NCT06219941) of sonesitatug vedotin monotherapy in patients with claudin 18.2-positive advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers. Results demonstrated clinically meaningful efficacy, with a promising objective response rate and manageable safety profile. Circulating tumor DNA molecular responses were observed in the majority of evaluable patients, supporting further investigation of this antibody-drug conjugate in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
